# Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With Metronomic VEX in Advanced Triple-negative Breast Cancer

Source: https://onco.cc/trials/nct06229067/  
OnCo record `nct06229067` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of adebrelimab, vinorelbine, cyclophosphamide and capecitabine in triple-negative breast cancer, run by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, not yet recruiting.

## Summary

Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With Metronomic VEX in Advanced Triple-negative Breast Cancer is a phase 2, randomised interventional study registered as NCT06229067 by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, with a registry enrolment figure of 182 participants, started 2024-01-19 and due to reach its primary completion in 2025-01-19. Interventions recorded: Adebrelimab; Vinorelbine; Cyclophosphamide (tablet); Capecitabine. Conditions listed: Breast Cancer; Triple Negative Breast Cancer. Triple-negative eligibility wording from the registry: "Participants with clear clinical records of metastatic triple-negative breast cancer, as specified in the American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT06229067
- Phase: 2
- Setting: Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With Metronomic Chemotherapy of Vinorelbine, Cyclophosphamide and Capecitabine (VEX) Regime in Advanced Triple-negative Breast Cancer: a Multicenter, Randomized, Phase II Study
- Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Enrolled: 182

## Sources

- ClinicalTrials.gov NCT06229067: https://clinicaltrials.gov/study/NCT06229067

## Connected records

- cancers: [Metastatic triple-negative breast cancer](https://onco.cc/cancers/tnbc-metastatic/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Adebrelimab](https://onco.cc/drugs/adebrelimab/), [Capecitabine](https://onco.cc/drugs/capecitabine/), [Cyclophosphamide](https://onco.cc/drugs/cyclophosphamide/), [Vinorelbine](https://onco.cc/drugs/vinorelbine/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06229067.json